A Drug-related Problem Risk Assessment Tool (DRP-RAT) for use by home care practical nurses
|
|
- Mervin Osborne
- 6 years ago
- Views:
Transcription
1 A Drug-related Problem Risk Assessment Tool (DRP-RAT) for use by home care practical nurses Maarit Dimitrow, PhD (Pharm) University of Helsinki Finland
2 Background The demand for long-term home health care services for the aged is growing Those needing home care (HC) are increasingly older and have more complex health problems In Finland, practical nurses (PNs) have 3-year vocational education that concentrates mainly on technical nursing rather than pharmacotherapy
3 Background PNs working in HC are those who make regular home visits to the elderly => PNs are in a key position to monitor and notice changes in their clients health status including positive and negative outcomes of possible drug treatments Due to lacking physician resources in HC, the physician-conducted home visits are rare => PNsʼ role in medication risk management is pronounced
4 DRP-RAT PNs need a practical tool for identifying problems related to drug treatments => Development and validation an easy-to-use Drugrelated Problem Risk Assessment Tool (DRP-RAT) for PNs caring for home-dwelling aged 65 years PNs need training to use the Tool PNs conduct the risk assessments during their normal home visits in collaboration with the HC client (if possible) PNs report their risk assessments to other healthcare providers
5 Development of the draft DRP-RAT 1. Two systematic literature reviews 2. Expertice of the research group 3. Consultation of a geriatrician not involved in the research group Content validation of the draft DRP- RAT 3-round Delphi survey with a panel of 18 experts in geriatric care and pharmacotherapy Feasibility of the final DRP-RAT Conducted among practical nurses in home care of two towns in southern Finland Testing the validity of the final DRP- RAT in clinical practice An experienced geriatricianʼs reliability evaluation of PNsʼ risk assessments Geriatrician identifyed the clinically most significant DRPs Phase I Development Phase II Validation process
6 Faculty of Pharmacy / Maarit Dimitrow
7 Is there anyone who determines whether the client takes his/her medicines? (added based on the feasibility study)
8 OTC High risk medicines Polypharmacy
9 Involving the client and his/her proxy to clientʼs care Fall tendency Symptoms suggestive of ADRs
10 Clientʼs health status Potential problems with transfer of clinical patient data
11 Involving the client/care giver in clientʼs care Adherence
12 Interventions for resolving the problems Increases the awareness among PNs and the aged of options to improve medication safety
13 Symptoms suggestive of ADRs When developing the DRP-RAT we had to take into account the PNʼs ability to answer the items of the tool It is not useful to ask the PNs if the clients uses anticholinergic medicines, sedatives or medicines that may cause hyponatremia etc. Thus, we decided to ask the PNs if their clients have symptoms suggestive of adverse drug reactions (ADRs) that these problematic medicines may cause The symptoms listed in the Tool include ADRs of a wide range of medicines (e.g., anticholinergics, sedatives, neuroleptics, diuretics, hypoglycemic, diuretics, blood pressure medications, etc.)
14
15 Main results of the feasibility study Participants: 36 PNs Time spent to complete the DRP-RAT minutes; mean 20±8 minutes The PNs identified 88% of the risk medicines listed in the Tool Challeges the PNs met in completing the tool Generic names of medicines Time resctrictions Short client contacts Faculty of Pharmacy / Maarit Dimitrow
16 Geriatricianʼs reliability evaluation of PNsʼ risk assessments Faculty of Pharmacy / Maarit Dimitrow
17 Outline of the study Participants: A clinically experienced geriatrician 26 home care PNs 46 home care clients 1. First phase of the study: The PNs conducted risk assessment for their clients using the DRP-RAT during their normal home visits The PNsʼ risk assessments were forwarded to the research geriatrician ifaculty of Pharmacy / Maarit Dimitrow
18 2. Second phase of the study: DRP risk assessments and medication reviews by the geriatrician The geriatrician reviewed the same clientsʼ medications using three different review methods: Method 1: Review based on the PN-completed DRP-RAT information and the medication list printed from the health centerʼs medical records Method 2: Review based on the health center s medical records ( gold standard ) of the study) Medical records encompass the following patient data: a) visits in health center, b) clinical examinations (health status, anamnesis, conclusions), c) medication lists, d) laboratory test results, e) hospitalizations, f) HC workers open comments about their home visits Method 3: Review based on Methods 1 and 2 together = all client information available Faculty of Pharmacy / Maarit Dimitrow
19 Geriatricianʼs assessment of clinical importance of the items in identifying risks for clinically significant drug-related problems in study sample Based on each review the geriatrician was asked to classify the patients as an risk patient or not an at risk patient Risk patient: a patient is at risk for clinically significant DRPs needing more comprehensive medication review If the geriatrician classified the client as an at-risk patient based on Method 1 (PN-completed DRP- RAT information and medication list) she was asked to tick those PN-identified risk predicting notes in the Tool that she regarded as clinically significant risk factors Faculty of Pharmacy / Maarit Dimitrow
20 Traffic lights of risks Risk predicting factor Has the client had any of the following symptoms in the last 4 weeks? drowsiness, fatigue, skin rash or itch, dizziness, urination problems, muscle pains, nausea, diarrhea, constipation, dizziness when getting up, recurrent falls, swellings, memory problems, confusion, visual problems, stiffness, troubles in walking, low blood pressure; systolic pressure under 110 mmhg (n=44) Does the client have more than one physician involved in his/her care? (e.g., general practitioners, specialists, private practitioners) (n=44) Has the client had more than one fall in the past 12 months? (n=44) Does the client use any of the following medicines (please check the ones used)? amiodarone, carbamazepine, digoxin, fluoxetine, lithium, methotrexate, theophylline, warfarin (n=44) Prevalence in the study sample 40 (yes) (91%) 22 (yes) (50%) 18 (yes) (41%) 16 (yes) (36%) Clinical Importance of the of the questions in identifying risks for clinically significant drug-related problems Faculty of Pharmacy / Maarit Dimitrow
21 Risk predicting factor Traffic lights of risks Has the client had troubles in a) remembering to take the medicines? b) following the medicines regimen? c) knowing what his or her medicines are used for? d) affording the medicines (i.e., economic problems)? e) opening the drug bottles or packages or managing with medicines related therapeutic devices? (n=44) Does the client use medicines that a) relieve pain by reducing inflammation (does not apply to paracetamol)? b) elevate the rate of urination (diuretics)? c) are intended to lower the cholesterol level (statins)? ) d) the physician does not know about? (n=44) Have the client's relatives/proxies expressed their concern about the client's medicine use? (n=43) Has the client started a new medicine in the last 4 weeks? (excluding different brands of the same active incredient) (n=44) Prevalence in the study sample 30 (yes) (68%) 35 (yes) (80%) 7 (yes) (16%) 7 (yes) (16%) Clinical Importance of the of the questions in identifying risks for clinically significant drug-related problems Farmasian tiedekunta / Henkilön nimi / Esityksen nimi
22 Implications for practice DRP-RAT: Can assist in identifying clients needing medication review Provides additional information for pharmacists who conduct medication reviews Educational implications
23 An example of an operational model (case Lohja, Toivo et. al. 2017) Practical Nurses Update of the medication lists Risk assessment with DRP-RAT (Clinical tests) Coordinating pharmacist Preliminary assessent of the medication using Medication lists Risk assessments Available databases (pharmacokinec and -dynamic interactions) Coordinating pharmacist and physician Shared decisionmaking for further actions Physician, nurse, pharmacist Case-spesific actions, e.g., prescription review, MR, CMR (physician) Carrying out the decided actions (pharmacist) Follow up after 3 months (nurse)
24 First assignment Think ideas how to implement the DRP-RAT in your health care system? Other ideas to benefit the DRP- RAT? Faculty of Pharmacy / Maarit Dimitrow
25 Second assignment The case of Mrs. K Mrs. K is an 86 years old lady, living alone in her own house. Home care practical nurse Miss. A visits her 3 times a week. Mrs. K suffers from cardiac failure, hypertension, diabetes mellitus, osteoarthritis, depression, troubles with sleeping and constipation. Earlier, she also has had several urinary tract infections. Most of her medicines are dispensed by automated dose dispensing (i.e., regularly used medicines are machine packed into unit dose bags for each time of administration), home care practical nurse administers the rest (i.e., buprenorphine plaster, local estrogen). Mrs. K takes her daily tablets (except the plasters and local estrogen) on her own. During the last weeks Miss. A has noticed that Mrs. K has been tired and forgetful, from time to time she has not taken all her dispensed medicines. Miss. A wondered if the used medicines could cause these symptoms. As Miss. A had been trained on the content and use of the DRP-RAT by her home care organization, she conducted the medication risk assessment during her next home visit to Mrs. K. She also printed Mrs. K medication list from health centre s medical records and compared the medicines Mrs. K. really uses with the medication list. Farmasian tiedekunta / Henkilön nimi / Esityksen nimi
26 The case of Mrs. K Which do you think are the most essential PN-reported risk predicting factors in the completed DRP-RAT? Justify your opinion Which medicines and/or what combination of medicines that Mrs. K uses may cause her symptoms? Use databases, Beers criteria etc. Do you agree with the PNʼs recommendations for action? If not, what would you prefer Mrs. K for further actions? Justify your opinion Farmasian tiedekunta / Henkilön nimi / Esityksen nimi
27 Thank You! Farmasian tiedekunta / Henkilön nimi / Esityksen nimi
Selecting the right patient for medication reviews
Selecting the right patient for medication reviews Prof dr Petra Denig, Clinical Pharmacy & Pharmacology, University Medical Center Groningen, the Netherlands 2 Who is in need of medication review: can
More informationPatient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR
Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any
More informationPRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic
0 PRODUCT MONOGRAPH FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION Anti-inflammatory, Analgesic INFORMATION FOR THE PATIENT FLOCTAFENINE, which has been prescribed to you
More informationThis leaflet answers some common questions about Momex SR Tablets.
Momex SR Modified (Sustained) Release Tablets [Morphine sulphate] CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Momex SR Tablets. It does not contain
More informationPHOLCODINE. Please follow the instructions on the packaging of the medicine you purchased and in this leaflet before you start using pholcodine.
PHOLCODINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains pholcodine. This leaflet is intended to provide information on the active ingredient
More informationPRESCRIBING IN THE ELDERLY. CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas
PRESCRIBING IN THE ELDERLY CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas LEARNING OUTCOMES Medicines Optimisation The effects of aging on health and medicines. Polypharmacy Acute Kidney
More informationAll medicines have risks and benefits. Your doctor has weighed the risks of you taking Triprim against the benefits he or she expects it will have.
Triprim Tablets Trimethoprim Tablets Consumer Medicine Information What is in this leaflet? The leaflet answers some common questions about Triprim tablets. It does not contain all the available information
More informationPatient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet
Page 1 of 6 Patient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet What type of drug is it? BuTrans transdermal patches
More informationAdepu and Adusumilli: Drug-related Problems in Patients with Chronic Diseases in South India
Assessment of Drug-related Problems in Patients with Chronic Diseases through Health Status Survey in a South Indian Rural Community Setting R. ADEPU* AND P. K. ADUSUMILLI Department of Pharmacy Practice,
More informationDetecting inappropriate prescribing for older patients at the community pharmacy
Detecting inappropriate prescribing for older patients at the community pharmacy Eline Tommelein, Els Mehuys, Koen Boussery Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University,
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Pregabalin. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Pregabalin For the Treatment of Pain This information is not intended to replace your doctor s advice.
More informationMedication Management When Caring for Seniors at Home
Medication Management When Caring for Seniors at Home White Paper May 24, 2013 2013 Physician s Choice Private Duty http://private-duty.pchhc.com 1 Proper medication management for seniors who live at
More informationFor many people, the warnings for a medication can read like the fine print of a home mortgage.
October 16, 2017 HEALTH NEWS Most Consumers Unaware of Dangers in Mixing Alcohol and Common Drugs Patient advocate group NCPIE wants to remind patients and doctors about drug interactions. For many people,
More informationKetorolac injection. Supportive care
Supportive care Ketorolac injection Supportive care: specialist medicines This leaflet provides information on a medicine called ketorolac which is used to treat pain that is difficult to control. It is
More informationPATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:
SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You
More informationIf you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA
If you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA IMPORTANT SAFETY INFORMATION WARNING: HYPONATREMIA See full prescribing information for complete boxed warning. NOCTIVA
More informationDiuretics Looking for more health information?
2010 Diuretics Diuretics Why do I need this medication? Diuretics are fluid pills or water pills that are used to help the body get rid of water. They are used to treat high blood pressure and fluid retention
More informationPain CONCERN. Medicines for long-term pain. Opioids
Pain CONCERN Medicines for long-term pain Opioids Opioids are a group of medicines that come from the extract of poppy seeds or other medicines that work in the same way. Types of opioid The first opioids
More informationTRIPROLIDINE. Please read this leaflet and the packaging of the medicine you purchased, carefully before you start using triprolidine.
TRIPROLIDINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains triprolidine. This leaflet is intended to provide information on the active ingredient
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr BACLOFEN Baclofen Tablets 10 mg and 20 mg This leaflet is part III of a three-part "Product Monograph" published when BACLOFEN was approved for sale in Canada and is designed
More informationGeriatric Medicine Clerkship Orientation. Aval-Na Ree Green (modified by Huai Cheng)
Geriatric Medicine Clerkship Orientation Aval-Na Ree Green (modified by Huai Cheng) Welcome! Goals The geriatric clerkship is designed to prepare medical students to provide evidence-based, competent,
More informationPerjeta Contains the active ingredient pertuzumab (rch)
Perjeta Contains the active ingredient pertuzumab (rch) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Perjeta. It does not contain all the available
More informationAmal AL-Anazi, BSc.(Pharm) Medication Safety Officer In Eastern Region
Risks Of Polypharmacy Amal AL-Anazi, BSc.(Pharm) Medication Safety Officer In Eastern Region What is Polypharmacy? Polypharmacy means many drugs. In practice, polypharmacy refers to the use of more medication
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationNEOFEN 60 mg suppository
PACKAGE LEAFLET: INFORMATION FOR THE USER NEOFEN 60 mg suppository IBUPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationWelcome participants, introduce the expert, and briefly outline today s session.
SESSION CONTENT 5.1 Welcome and outline (2 min) Welcome participants, introduce the expert, and briefly outline today s session. 5.2 Review homework and exercises (15 min) Review participants personal
More informationTREANA 5mg and 10mg Film-coated Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER TREANA 5mg and 10mg Film-coated Tablets OLANZAPINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationConsumer Medicine Information
MAXOLON Consumer Medicine Information Metoclopramide hydrochloride 10mg Tablet What is in this leaflet This leaflet answers some common questions about Maxolon. It does not contain all the available information.
More information21st century community pharmacy
From dispensing and counseling to patient care (?) 21st century community pharmacy Saija Leikola Development manager, PhD Pharmac Finland Oy WHAT WE DO NOW? Dispense Counsel, give instructions, check DDIs
More information1. What Solpadol is and what it is used for
PATIENT INFORMATION LEAFLET SOLPADOL 30mg/500mg CAPLETS Codeine Phosphate and Paracetamol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
More informationMidazolam Injection Midazolam
Midazolam Injection Midazolam Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Midazolam Injection. It does not contain all the available information.
More informationManaging medicines in older people. Jane Noble and Caroline Ralph
Managing medicines in older people Jane Noble and Caroline Ralph Where? Community Hospital Care Home What? Prescribing Dispensing Administering Case 1 84 year old lady Admitted with reduced mobility Recurrent
More informationDuro-Tuss Dry Cough Liquid plus Nasal Decongestant Pholcodine (fol-co-dean); Pseudoephedrine hydrochloride (sue-doe-eff-eh-drine hydro-klor-ide)
Duro-Tuss Dry Cough Liquid plus Nasal Decongestant Pholcodine (fol-co-dean); Pseudoephedrine hydrochloride (sue-doe-eff-eh-drine hydro-klor-ide) Consumer Medicine Information What is in this leaflet This
More informationCase Study Activity: Strategies to Support the Safe Use of Acetaminophen
Case Study Activity: Strategies to Support the Safe Use of Acetaminophen Case 3: Preventing Therapeutic Duplication With Over-the-Counter Acetaminophen Products Activity Preview Acetaminophen is one of
More informationPATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE
SCHEDULING STATUS: S5 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: ZOXADON 0,5 mg: Each tablet contains 0,5 mg risperidone. ZOXADON 1 mg: Each tablet contains 1 mg risperidone. ZOXADON 2 mg: Each
More informationPharmaceutical Care for Geriatrics
Continuing Professional Pharmacy Development Program Pharmaceutical Care for Geriatrics Presented by: Alla El-Awaisi; MPharm, MRPharmS, MSc Event Organizer: Dr. Nadir Kheir; PhD Disclaimer: PRESENTING
More informationOnglyza CONSUMER MEDICINE INFORMATION
What is in this leaflet Onglyza Saxagliptin 2.5 mg and 5 mg film coated tablets CONSUMER MEDICINE INFORMATION This leaflet answers some of the common questions people ask about Onglyza. It does not contain
More informationComprehensive Medication History Interview Form
Comprehensive Medication History Interview Form Introduction Introduce self and profession. Explain purpose of session. PharmD Completing Form: Does the patient wish for a family member to be present during
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate)
PACKAGE LEAFLET: INFORMATION FOR THE USER DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate) Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen
PACKAGE LEAFLET: INFORMATION FOR THE USER EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking Easofen Max Strength Tablets because it contains
More informationRANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets RANITIDINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationFlecainide BNM. Please read this leaflet carefully before you start taking Flecainide BNM.
1 Consumer Medicine Information Flecainide acetate Tablets 50 mg & 100 mg What is in this leaflet Please read this leaflet carefully before you start taking. This leaflet answers some common questions
More informationHave you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider.
Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider. 1 Benefits of Clozapine Clozapine may work when other medications don t. Doctors
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium
PACKAGE LEAFLET: INFORMATION FOR THE USER Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium Read all of this leaflet carefully before you start taking this medicine because it contains
More informationDeconstructing Polypharmacy. Alan B. Douglass, M.D. Director
Deconstructing Polypharmacy Alan B. Douglass, M.D. Director Recognize this patient? Mrs. Brown- 82 years young Active Medical Problems Hypertension Hyperlipidemia Type 2 Diabetes Peripheral edema Osteoarthritis
More informationSPASMEX FORTE 5mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SPASMEX FORTE 5mg tablets TROSPIUM This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationAripiprazole Accord 5, 10, 15 and 30 mg film-coated tablets
Aripiprazole Accord 5, 10, 15 and 30 mg film-coated tablets EDUCATIONAL MATERIAL FOR THE PATIENTS AND THEIR CAREGIVERS Introduction Your doctor has diagnosed you with bipolar I disorder and prescribed
More informationPLEASE FILL OUT & RETURN
PLEASE FILL OUT & RETURN MEDICATION THERAPY MANAGEMENT (MTM) PROGRAM CONSENT and AUTHORIZATION for RELEASE of INFORMATION I agree to participate in the Medication Therapy Management (MTM) Program. I will
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Duloxetine. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Duloxetine For the Treatment of Pain This information is not intended to replace your doctor s advice.
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationXYZAL 5 MG FILM-COATED TABLET
XYZAL 5 MG FILM-COATED TABLET Levocetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However,
More informationIt does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.
STILNOX zolpidem tartrate Consumer Medicine Information WARNING: ZOLPIDEM MAY BE ASSOCIATED WITH UNUSUAL AND POTENTIALLY DANGEROUS BEHAVIOURS WHILST APPARENTLY ASLEEP. THESE HAVE INCLUDED SLEEP WALKING,
More informationPackage Leaflet: Information for the User. Kemadrin tablets 5 mg procyclidine hydrochloride
Package Leaflet: Information for the User Kemadrin tablets 5 mg procyclidine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Cyclizine Lactate 50 mg/ml Injection
Package leaflet: Information for the user Cyclizine Lactate 50 mg/ml Injection Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationSafe Medication Use. Patient Teaching Slides
Safe Medication Use Patient Teaching Slides 3 Ways to Improve Medication Safety 1. Talk to your Doctor or Pharmacist about Your Medications 2. Organize, Store, Secure, and Dispose of Your Medications Safely
More informationPackage leaflet: Information for the patient. Torarese 2.5 mg tablets Torarese 5 mg tablets Torarese 10 mg tablets Torarese 20 mg tablets.
Package leaflet: Information for the patient Torarese 2.5 mg tablets Torarese 5 mg tablets Torarese 10 mg tablets Torarese 20 mg tablets Torasemide Read all of this leaflet carefully before you start taking
More informationMETHYLDOPA 250 mg Film-coated Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER METHYLDOPA 250 mg Film-coated Tablets METHYLDOPA This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationPHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate
CONSUMER MEDICINE INFORMATION PHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate What is in this leaflet This leaflet answers some common questions
More informationparacetamol Please read this leaflet carefully before you are given Paracetamol BNM.
1 Consumer Medicine Information paracetamol 1000 mg/100 ml solution for injection What is in this leaflet Please read this leaflet carefully before you are given. This leaflet answers some common questions
More informationPackage leaflet: Information for the user. Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol)
Package leaflet: Information for the user Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol) Read all of this leaflet carefully before you start taking this medicine because
More informationCosudex. Bicalutamide 50 mg Tablets CONSUMER MEDICINE INFORMATION
Cosudex Bicalutamide 50 mg Tablets CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some of the common questions people ask about Cosudex. It does not contain all the information
More informationMyfortic Transplant Coordinator Survey: Defining the perceptions of generic mycophenolate mofetil
Myfortic Transplant Coordinator Survey: Defining the perceptions of generic mycophenolate mofetil July 28, 2010 Prepared for: Steve Arcona, PhD Director, Outcomes Research Novartis Pharmaceuticals Corporation
More informationConsumer Medicine Information
Consumer Medicine Information Trade Name: ZOLPIDEM-DP Active Ingredient: Zolpidem tartrate Warning: Zolpidem may be associated with unusual and potentially dangerous behaviours whilst apparently asleep.
More informationFrom medicines reconciliation to medicines review. Dr. Fatma Karapinar Hospital pharmacistepidemiologist
From medicines reconciliation to medicines review Dr. Fatma Karapinar Hospital pharmacistepidemiologist Conflict of interest Nothing to disclose Questions Medication review is more important than medicines
More informationAVIOMARIN 50 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationEDEMID FORTE 500mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER EDEMID FORTE 500mg tablets FUROSEMIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationPATIENT INFORMATION LEAFLET TEXAMER
SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: film-coated tablets Read all of this leaflet carefully because it contains important information for you. is available without a doctor s prescription,
More informationof LDL and HDL cholesterol.
Ezetimibe Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain all the available information. It does not take the place of talking
More informationPOLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS
PROPOSED FINAL PATIENT INFORMATION LEAFLET FOR POLLENTYME TABLETS & POLLENTYME S PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS
More informationYOUR GUIDE TO ARIPIPRAZOLE Patient/Caregiver Information Brochure
YOUR GUIDE TO ARIPIPRAZOLE Patient/Caregiver Information Brochure Aripiprazole Dr. Reddy's 5, 10, 15 and 30 mg film-coated tablets Aripiprazole Dr. Reddy s 1 mg/ml Oral Solution Introduction Your doctor
More informationMedical History Form
Medical History Form Name: ; Birth date: / / ; Date: / / Person filling out form: ; Relationship: Thank you for taking the time to fill out this valuable information. This allows us to provide the best
More informationPGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne
Public consultation on Delegated Act on Post-Authorisation efficacy studies PGEU RESPONSE INTRODUCTION The Pharmaceutical Group of the European Union (PGEU) is the association representing community pharmacists
More informationIt is used to treat or prevent upset stomach and throwing up. What do I need to tell my doctor BEFORE I take this drug?
PATIENT & CAREGIVER EDUCATION Ondansetron Brand Names: US Zofran; Zofran ODT [DSC]; Zuplenz Brand Names: Canada Ondissolve ODF; Zofran ODT What is this drug used for? It is used to treat or prevent upset
More informationFor the Patient: Vemurafenib Other names: ZELBORAF
For the Patient: Vemurafenib Other names: ZELBORAF Vemurafenib (vem ue raf e nib) is a drug that is used to treat some types of cancer. It is a tablet that you take by mouth. Tell your doctor if you have
More informationPatient/Caregiver Information Brochure For Bipolar I Disorder in Adolescents
Patient/Caregiver Information Brochure For Bipolar I Disorder in Adolescents Date of approval: March 2013 Mercury number: 570HQ13NP00107-01-IE 786203127-001_Patient_Caregiver_IRELAND_v4.indd 1 20/03/2013
More informationMY DISCUSSION GUIDE. Get the most out of your OCALIVA treatment.
PBC I am currently taking OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Get the most out of your OCALIVA treatment. This guide is not intended to replace the advice of your healthcare team. All decisions
More informationCeclor CD cefaclor monohydrate sustained release tablets
Ceclor CD cefaclor monohydrate sustained release tablets Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Ceclor CD. It does not contain all
More informationAnnual Exam Review. Medications: Medication Strength (mg) Directions ( how many pills and how many times a day)
Annual Exam Review Name Medications: Medication Strength (mg) Directions ( how many pills and how many times a day) Overall health: Good Fair Poor Men : When was the last time you had: Prostate exam Prostate
More informationDulcolax 5 mg, film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Dulcolax 5 mg, film-coated tablets BISACODYL This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which
More informationMedication Safety Challenges in Older Adults
Panel Discussion 2, Patient Safety in an Ageing Society 13 April 2018, Tokyo, Japan Medication Safety Challenges in Older Adults Midori Hirai MD, PhD Hyogo Blood Center Japanese Red Cross Older Adults
More informationRABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationBisacodyl Laxative (Pharmacy Health)
Bisacodyl Laxative (Pharmacy Health) Each Enteric Coated Tablet contains 5 mg Bisacodyl BP/Ph. Eur Gastro resistant Tablets What is in this leaflet This leaflet answers some common questions about Bisacodyl
More informationThis leaflet answers some common questions about ATIVAN. It does not contain all of the available information.
Ativan Lorazepam Tablets Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about ATIVAN. It does not contain all of the available information. It does not
More informationPROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC.
SCHEDULING STATUS: S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNAFLOC 250 (tablets) DYNAFLOC 500 (tablets) DYNAFLOC 750 (tablets) Read this entire leaflet carefully before you start taking
More informationColofac mebeverine hydrochloride
Colofac mebeverine hydrochloride Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Colofac. It does not contain all the available information.
More informationPackage leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)
Package leaflet: Information for the user Colecalciferol 3000 IU/ml Oral Solution (colecalciferol) Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPATIENT INFORMATION LEAFLET
PPM Code: E1981 PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S2 PROPRIETARY NAME DOSAGE FORM: film coated tablets Read all of this leaflet carefully because it contains important information for you.
More informationHow it works. Use in children
GenRx Allopurinol contains the active ingredient, (al-oe-pur-in-ol) For a copy of a large print leaflet, Ph: 1800 195 055 Consumer Medicine Information What is in this leaflet Read this leaflet carefully
More informationMIDAZOLAM APOTEX Solution for Injection Contains the active ingredient midazolam
MIDAZOLAM APOTEX Solution for Injection Contains the active ingredient midazolam Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet Read this leaflet
More informationBuprenorphine Patch (Transtec Patch)
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Buprenorphine Patch (Transtec Patch) For the Treatment of Pain Contents Page What is a transtec patch?...
More informationPharmacology in the Elderly
Pharmacology in the Elderly James Hardy Geriatrician, Royal North Shore Hospital A recent consultation Aspirin Clopidogrel Warfarin Coloxyl with senna Clearlax Methotrexate Paracetamol Pantoprazole Cholecalciferol
More informationZOLPIDEM PHARMACOR Zolpidem tartrate
Zolpidem tartrate Consumer Medicine Information Warning: Zolpidem may be associated with unusual and potentially dangerous behavior whilst apparently asleep. These have included sleep walking, driving
More informationColdrex MaxGrip Lemon Powder for oral solution
PACKAGE LEAFLET: INFORMATION FOR THE USER Coldrex MaxGrip Lemon Powder for oral solution PARACETAMOL, PHENYLEPHRINE, ASCORBIC ACID This leaflet is a copy of the Summary of Product Characteristics and Patient
More informationENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS
ENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS Philip J. Schneider, MS, FASHP The University of Arizona College of Pharmacy Learning Objectives: Describe the medication-use system and all interdependent
More informationWellness along the Cancer Journey: Palliative Care Revised October 2015
Wellness along the Cancer Journey: Palliative Care Revised October 2015 Chapter 3: Addressing Cancer Pain as a part of Palliative Care Palliative Care Rev. 10.8.15 Page 360 Addressing Cancer Pain as Part
More informationOlanzapine generichealth tablets Olanzapine benzoate
CONSUMER MEDICINE INFORMATION Olanzapine generichealth tablets Olanzapine benzoate What is in this leaflet This leaflet is designed to provide you with answers to some common questions about this medicine.
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr SYLVANT pronounced SILL-vant siltuximab for injection Read this carefully before you start taking SYLVANT and each
More information